secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2026-05-26T11:08:51+00:00
Accession:  0001453687-26-000087
Event type: debt
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.03, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian secures up to $150M debt facility; CMO resigns; Phase 3 data expected Q1 2027
--------------------------------------------------------------------------------

- Secured up to $150M credit facility with K2 HealthVentures; initial $50M tranche funded at close on May 22, 2026.
- Term loans bear interest at 8.95% or prime+2.20% (whichever greater); matures June 1, 2030 with monthly amortization from July 2029.
- CMO Milos Miljkovic resigns effective May 31, 2026; will receive severance including six months' salary and COBRA coverage.
- Phase 3 AURORA topline data for Descartes-08 in myasthenia gravis expected in Q1 2027; BLA filing planned for mid-2027.
- Cash runway extended into 2028; Phase 2 TRITON and Phase 1/2 HELIOS data expected in H1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368726000087/0001453687-26-000087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368726000087/rnac-20260522.htm
  HTML page:      https://secwatch.observer/filing/0001453687-26-000087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer